Bronstein Ben 4

What Happened

• Ben Bronstein, a director of Aldeyra Therapeutics (ALDX), was granted three derivative equity awards on 2026-06-09 totaling 80,286 shares (70,000; 5,309; 4,977). Each grant was reported at an acquisition price of $0.00 and reported as derivative securities (Form 4, transaction code A).
• These awards are not open-market purchases or sales; they are grants commonly used for director compensation and do not represent an immediate cash transaction or sale.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (timely filing).
• Reported acquisition price: $0.00 for each grant; total shares granted: 80,286.
• Shares owned after the transaction: not specified in this Form 4.
• Vesting/vesting conditions (from footnotes):
  • F1: 100% exercisable on the one‑year anniversary if the reporting person remains a director through the vesting date.
  • F2: 100% exercisable on the one‑year anniversary if the reporting person remains a member of the Nominating/Corporate Governance Committee through the vesting date.
  • F3: 100% exercisable on the one‑year anniversary if the reporting person remains a member of the Audit Committee through the vesting date.
• Transaction type: Grant/Award of derivative securities (code A); no 10b5-1 plan or tax-withholding note disclosed.

Context

• These are derivative awards that become exercisable (vest) after one year subject to continued board/committee service. They do not indicate an immediate purchase or sale of stock and often reflect routine director compensation.